Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Topas Therapeutics Serves as Exclusive Translational Partner for Collaborative Research Center Focused on Liver Inflammation at University Medical Center Hamburg-Eppendorf

Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million. Topas Therapeutics will act as exclusive partner for indication expansions and translation of research results into clinical development. Hamburg, 25th…

Dr Enno Klussmann Joins Mironid’s SAB

January 15, 2018 – Mironid is delighted to announce the appointment of Dr Enno Klussmann to our Scientific Advisory Board Dr. Klussmann is currently a group leader at the Max Delbrück Center for Molecular Medicine (MDC) Berlin, Germany. Dr Klussmann is internationally renowned for his…

Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)

LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, will present an update on its Phase 1b PHAROAH trial at the 12th Annual Scientific Assembly…